GT Biopharma (GTBP) FCF/Share TTM: History & Chart

GT Biopharma, Inc.(GTBP)

Biotechnology · San Francisco, CA

$6.30+0.14 (+2.27%)

Delayed quote: Oct 6, 2026, 1:27 PM EDT

About GT Biopharma, Inc.

GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.

San Francisco, CA

1 employees

www.gtbiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael Martin Breen

View full financials

FCF/Share TTM

Basis: latest reported fiscal quarter (Q2 FY2026). Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly fcf/share TTM is ($9.29). Trailing free cash flow divided by the latest matching quarter’s diluted weighted-average shares (basic shares when diluted shares are unavailable).

Free Cash Flow|FCF Yield|Price/FCF Ratio|Cash Flow Statement

FCF/Share TTM

GTBP FCF/Share TTM

$-9.29

Four consecutive fiscal quarters of free cash flow divided by the latest matching quarter’s weighted-average shares; no daily interpolation. Q2 FY2026 (2026-06-30): $-9.29.

+100.00% over 10Y

Unavailable TTM periods

Four matching fiscal cash-flow quarters and a matching share count are required. Unsupported windows remain N/A; single-quarter per-share values are not substituted.

7 source periods with unavailable TTM values

Cash-flow period end	FCF/Share TTM
2015-12-31	N/A
2011-03-31	N/A
2010-09-30	N/A
2010-06-30	N/A
2003-03-31	N/A
2002-12-31	N/A
2002-09-30	N/A

Quarterly FCF/Share TTM History

Period	FCF/Share TTM	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	($9.29)	N/A	N/A
Q1 FY2026Period end 2026-03-31	($10.88)	N/A	N/A
Q4 FY2025Period end 2025-12-31	($58.56)	N/A	N/A
Q3 FY2025Period end 2025-09-30	($72.07)	N/A	N/A
Q2 FY2025Period end 2025-06-30	($93.99)	N/A	N/A
Q1 FY2025Period end 2025-03-31	($116.66)	N/A	N/A
Q4 FY2024Period end 2024-12-31	($170.06)	N/A	N/A
Q3 FY2024Period end 2024-09-30	($139.69)	N/A	N/A
Q2 FY2024Period end 2024-06-30	($171.00)	N/A	N/A
Q1 FY2024Period end 2024-03-31	($183.00)	N/A	N/A
Q4 FY2023Period end 2023-12-31	($160.25)	N/A	N/A
Q3 FY2023Period end 2023-09-30	($203.05)	N/A	N/A
Q2 FY2023Period end 2023-06-30	($225.11)	N/A	N/A
Q1 FY2023Period end 2023-03-31	($297.97)	N/A	N/A
Q4 FY2022Period end 2022-12-31	($321.58)	N/A	N/A
Q3 FY2022Period end 2022-09-30	($42.26)	N/A	N/A
Q2 FY2022Period end 2022-06-30	($375.39)	N/A	N/A
Q1 FY2022Period end 2022-03-31	($395.64)	N/A	N/A
Q4 FY2021Period end 2021-12-31	($45.10)	N/A	N/A
Q3 FY2021Period end 2021-09-30	($330.48)	N/A	N/A
Q2 FY2021Period end 2021-06-30	($259.57)	N/A	N/A
Q1 FY2021Period end 2021-03-31	($495.22)	N/A	N/A
Q4 FY2020Period end 2020-12-31	($11.18)	N/A	N/A
Q3 FY2020Period end 2020-09-30	($32.23)	N/A	N/A
Q2 FY2020Period end 2020-06-30	($31.01)	N/A	N/A
Q1 FY2020Period end 2020-03-31	($17.72)	N/A	N/A
Q4 FY2019Period end 2019-12-31	($22.19)	N/A	N/A
Q3 FY2019Period end 2019-09-30	($964.87)	N/A	N/A
Q2 FY2019Period end 2019-06-30	($55.33)	N/A	N/A
Q1 FY2019Period end 2019-03-31	($61.95)	N/A	N/A
Q4 FY2018Period end 2018-12-31	($89.13)	N/A	N/A
Q3 FY2018Period end 2018-09-30	($2945.86)	N/A	N/A
Q2 FY2018Period end 2018-06-30	($2643.35)	N/A	+94.07%
Q1 FY2018Period end 2018-03-31	($2291.53)	N/A	+96.96%
Q4 FY2017Period end 2017-12-31	($46.05)	N/A	N/A
Q3 FY2017Period end 2017-09-30	($2715.19)	+93.91%	+99.31%
Q2 FY2017Period end 2017-06-30	($44589.74)	+40.87%	+88.89%
Q1 FY2017Period end 2017-03-31	($75406.25)	N/A	+85.10%
Q4 FY2016Period end 2016-12-31	($4279.38)	+98.91%	N/A
Q3 FY2016Period end 2016-09-30	($391285.71)	+2.49%	N/A
Q2 FY2016Period end 2016-06-30	($401285.71)	+20.72%	N/A
Q1 FY2016Period end 2016-03-31	($506166.67)	N/A	N/A
Q3 FY2015Period end 2015-09-30	($250052.95)	(1.17%)	(339.91%)
Q2 FY2015Period end 2015-06-30	($247158.21)	(36.27%)	(873.49%)
Q1 FY2015Period end 2015-03-31	($181368.74)	(97.03%)	(728.59%)
Q4 FY2014Period end 2014-12-31	($92052.95)	(61.95%)	(274.88%)
Q3 FY2014Period end 2014-09-30	($56842.11)	(123.89%)	+80.19%
Q2 FY2014Period end 2014-06-30	($25388.89)	(15.99%)	+25.08%
Q1 FY2014Period end 2014-03-31	($21888.89)	+10.86%	+97.65%
Q4 FY2013Period end 2013-12-31	($24555.56)	+91.44%	+55.22%
Q3 FY2013Period end 2013-09-30	($287000.00)	(746.89%)	(266.27%)
Q2 FY2013Period end 2013-06-30	($33888.89)	+96.37%	+59.39%
Q1 FY2013Period end 2013-03-31	($933000.00)	(1601.52%)	(733.04%)
Q4 FY2012Period end 2012-12-31	($54833.33)	+30.02%	+48.75%
Q3 FY2012Period end 2012-09-30	($78357.14)	+6.11%	+46.01%
Q2 FY2012Period end 2012-06-30	($83454.55)	+25.49%	+55.30%
Q1 FY2012Period end 2012-03-31	($112000.00)	(4.67%)	N/A
Q4 FY2011Period end 2011-12-31	($107000.00)	+26.28%	N/A
Q3 FY2011Period end 2011-09-30	($145142.86)	+22.26%	N/A
Q2 FY2011Period end 2011-06-30	($186714.29)	N/A	N/A
Q4 FY2010Period end 2010-12-31	($307000.00)	N/A	N/A
Q1 FY2010Period end 2010-03-31	($0.46)	+100.00%	+100.00%
Q4 FY2009Period end 2009-12-31	($312333.33)	+16.49%	(84.81%)
Q3 FY2009Period end 2009-09-30	($374000.00)	N/A	+13.43%
Q2 FY2009Period end 2009-06-30	$528000.00	N/A	N/A
Q1 FY2009Period end 2009-03-31	($129000.00)	+23.67%	+69.58%
Q4 FY2008Period end 2008-12-31	($169000.00)	+60.88%	+53.95%
Q3 FY2008Period end 2008-09-30	($432000.00)	+66.12%	(184.21%)
Q2 FY2008Period end 2008-06-30	($1275000.00)	(200.71%)	N/A
Q1 FY2008Period end 2008-03-31	($424000.00)	(15.53%)	(41.81%)
Q4 FY2007Period end 2007-12-31	($367000.00)	(141.45%)	+52.89%
Q3 FY2007Period end 2007-09-30	($152000.00)	N/A	+88.27%
Q2 FY2007Period end 2007-06-30	$37000.00	N/A	N/A
Q1 FY2007Period end 2007-03-31	($299000.00)	+61.62%	+84.30%
Q4 FY2006Period end 2006-12-31	($779000.00)	+39.89%	+66.10%
Q3 FY2006Period end 2006-09-30	($1296000.00)	+34.51%	+66.22%
Q2 FY2006Period end 2006-06-30	($1979000.00)	(3.88%)	+45.53%
Q1 FY2006Period end 2006-03-31	($1905000.00)	+17.10%	+49.09%
Q4 FY2005Period end 2005-12-31	($2298000.00)	+40.11%	+31.18%
Q3 FY2005Period end 2005-09-30	($3837000.00)	(5.62%)	(276.55%)
Q2 FY2005Period end 2005-06-30	($3633000.00)	+2.91%	(302.77%)
Q1 FY2005Period end 2005-03-31	($3742000.00)	(12.07%)	(489.29%)
Q4 FY2004Period end 2004-12-31	($3339000.00)	(227.67%)	(1279.75%)
Q3 FY2004Period end 2004-09-30	($1019000.00)	(12.97%)	(137.53%)
Q2 FY2004Period end 2004-06-30	($902000.00)	(42.05%)	(25.45%)
Q1 FY2004Period end 2004-03-31	($635000.00)	(162.40%)	N/A
Q4 FY2003Period end 2003-12-31	($242000.00)	+43.59%	N/A
Q3 FY2003Period end 2003-09-30	($429000.00)	+40.33%	N/A
Q2 FY2003Period end 2003-06-30	($719000.00)	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.